Melanoma trials recruiting in Alabama

All Melanoma trials nationally

Cities in Alabama

Recruiting trials in Alabama

• A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
  NCT04511013 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham, Fairhope, Mobile
• A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
  NCT05538130 · Phase: Phase 1 · Ages: 16 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
  NCT05297734 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham, Mobile
• DESTINY-PANTUMOUR04
  NCT07124000 · Phase: Not specified · Ages: 18 Years to 130 Years · Sex: All (male and female) · Alabama: Birmingham
• DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
  NCT07288112 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
  NCT03860883 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Mobile
• ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
  NCT05059444 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Project: Every Child for Younger Patients With Cancer
  NCT02402244 · Phase: Not specified · Ages: Up to 25 Years · Sex: All (male and female) · Alabama: Birmingham, Mobile
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Alabama: Birmingham, Mobile
• Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
  NCT05727904 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Alabama: Birmingham
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
  NCT04851119 · Phase: Phase 1, Phase 2 · Ages: 12 Months to 30 Years · Sex: All (male and female) · Alabama: Birmingham